January 15, 2018 – Mironid is delighted to announce the appointment of Dr Enno Klussmann to our Scientific Advisory Board Dr. Klussmann is currently a group leader at the Max Delbrück Center for Molecular Medicine (MDC) Berlin, Germany. Dr Klussmann is internationally renowned for his…
CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that, following discussions with the FDA, it has finalized…
RICHMOND, Va., December 19, 2017- Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected two new members to their Board of Directors for a term of three years. The election took place on December 14,…
LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 – Apellis Pharmaceuticals,Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, will present an update on its Phase 1b PHAROAH trial at the 12th Annual Scientific Assembly…
Acquisition Marks Further Success for the Epidarex Portfolio Bethesda, Md., December 7, 2017 – Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, today announced that its portfolio company, Harpoon Medical, Inc. (“Harpoon”), a pioneer in beating-heart repair for degenerative mitral regurgitation (DMR), has…
An interview with Sinclair Dunlop, Managing Partner at Epidarex Capital Sinclair Dunlop, Managing Partner at transatlantic venture capital firm Epidarex Capital, talks to Biotechand Money about the life science sub-sectors with unrealised potential, provides his top tips for early stage life science companies looking for…
Bethesda, Maryland, USA, and Edinburgh, UK: Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, is pleased to announce the initial public offering (“IPO”) of its portfolio company Apellis Pharmaceuticals, Inc. (“Apellis”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds…
Crestwood, Kentucky, Nov. 13, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its initial public offering of 10,714,000 shares of common…
Crestwood, Kentucky, Nov. 08, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its initial public offering of 10,714,000 shares of…
Device May Improve Quality and Frequency of Repair Baltimore, Maryland – A new study has found that a pioneering device to repair heart valves is safe and effective, and can reduce the invasiveness and side effects of conventional mitral valve surgery. The Harpoon Mitral Valve…